Cost Effectiveness of Paclitaxel/Cisplatin Compared with Cyclophosphamide/Cisplatin in the Treatment of Advanced Ovarian Cancer in Belgium

This publication has 24 references indexed in Scilit:

• A Bayesian Approach to Aid in Formulary Decision Making: Incorporating Institution-Specific Cost-Effectiveness Data with Clinical Trial Results
  Medical Decision Making, 2003
• Healthcare Resource Utilisation and Costs of Treating NSAID-Associated Gastrointestinal Toxicity
  PharmacoEconomics, 2001
• Patient management strategies and transplantation techniques in european stem cell transplantation centers offering breast cancer patients high-dose chemotherapy with peripheral blood stem cell support: a joint report from the EORTC and EBMT.
  2000
• Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results
  JNCI Journal of the National Cancer Institute, 2000
• Gains in Life Expectancy from Medical Interventions — Standardizing Data on Outcomes
  New England Journal of Medicine, 1998
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Cost‐effectiveness analysis of vaccination against hepatitis A in travellers
  Journal of Medical Virology, 1994
• The role of the sickness funds in the Belgian health care market
  Social Science & Medicine, 1994
• The Distinction Between Cost and Charges
  Annals of Internal Medicine, 1982
• The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice
  Epidemiology and Infection, 1949